Axonics, Inc. (AXNX) Misses Q2 EPS by 10c, Revenues Beat; Raises Revenue Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Axonics® Reports Second Quarter 2021 Financial Results
August 5, 2021 4:01 PM EDTTotal revenue of $45.9 million in 2Q21, including record SNM revenue of $40.2 million
Bulkamid® revenue of $5.7 million in first full quarter since acquisition
Fiscal year 2021 revenue guidance increased to a range of $186 million to $188 million
IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, today reported financial results for the second quarter ended June 30, 2021.
This quarters record revenue result reflects the growing... More
